Clinic
Lubbock County Hospital District
Lubbock County Hospital District was paid $14.43M by Medicaid between Jan 2018 and Dec 2024, across 210 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoLUBBOCK COUNTY HOSPITAL DISTRICT
LUBBOCK, TX 79415
LUBBOCK, TX 79415
33aNPI1821087164assigned 10/19/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$14.43M
24GClaims398,805
24DCodes billed210
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#33 of 320
Median peer was paid$205K
This provider vs. median70×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,365 | $606K | |
| 2019 | 9,363 | $318K | |
| 2020 | 10,879 | $291K | |
| 2021 | 95,281 | $3.05M | |
| 2022 | 105,792 | $3.60M | |
| 2023 | 99,919 | $4.09M | |
| 2024incomplete | 60,206 | $2.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 9,584 | 9,225 | $3.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 22,377 | 21,692 | $2.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 3,716 | 3,482 | $786K |
| G0378 | Hospital observation service, per hour | 5.0% | 1,780 | 1,681 | $723K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.9% | 10,071 | 9,326 | $703K |
| 59025 | Fetal non-stress test | 4.5% | 4,365 | 3,916 | $653K |
| 87428 | 3.3% | 8,732 | 8,503 | $470K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 4,763 | 4,652 | $439K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2.2% | 1,581 | 1,540 | $324K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 2.1% | 1,532 | 1,452 | $296K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.8% | 11,362 | 11,075 | $266K |
| 76770 | 1.8% | 1,484 | 1,459 | $262K |
198 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.8% | 9,797 | $257K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.6% | 232 | $231K |
| 80053 | Comprehensive metabolic panel | 1.6% | 30,340 | $226K |
| A0427 | Emergency ambulance ride, advanced life support | 1.5% | 2,086 | $216K |
| 87400 | 1.3% | 15,020 | $193K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 32,484 | $193K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,622 | $143K |
| 86703 | <1% | 7,288 | $139K | |
| 86780 | <1% | 7,130 | $135K | |
| 72082 | <1% | 1,090 | $133K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 846 | $129K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,512 | $128K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,885 | $119K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,364 | $102K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,070 | $83K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,190 | $82K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,802 | $78K |
| 86850 | <1% | 5,322 | $78K | |
| 54161 | <1% | 29 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,044 | $68K |
| 83880 | <1% | 2,629 | $62K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 210 | $60K |
| 86762 | <1% | 2,921 | $55K | |
| 72170 | <1% | 1,195 | $54K | |
| 87420 | <1% | 3,330 | $49K | |
| 76801 | <1% | 209 | $44K | |
| 86900 | <1% | 5,838 | $42K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,654 | $41K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,383 | $41K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 93 | $39K |
| 80050 | General health panel | <1% | 831 | $38K |
| 87340 | <1% | 3,154 | $37K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 196 | $36K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 539 | $31K |
| 81001 | <1% | 9,887 | $30K | |
| 84439 | <1% | 4,139 | $28K | |
| 86901 | <1% | 5,835 | $25K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,021 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,022 | $25K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,022 | $25K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 771 | $24K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 885 | $24K |
| 87081 | <1% | 2,348 | $24K | |
| 80061 | Lipid panel | <1% | 2,886 | $24K |
| 85027 | <1% | 6,684 | $23K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,465 | $22K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 53 | $22K |
| 84481 | <1% | 1,508 | $22K | |
| 73110 | <1% | 338 | $21K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,488 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 336 | $18K |
| 73090 | <1% | 345 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 981 | $17K |
| 83735 | <1% | 4,280 | $16K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,999 | $15K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 40 | $14K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 963 | $14K |
| 84703 | <1% | 2,414 | $14K | |
| 85730 | <1% | 3,689 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,797 | $13K |
| 85610 | <1% | 4,925 | $13K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,382 | $13K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,163 | $12K |
| 86140 | <1% | 1,997 | $12K | |
| 82950 | <1% | 1,550 | $12K | |
| 84484 | <1% | 2,715 | $12K | |
| 73590 | <1% | 270 | $12K | |
| 73630 | <1% | 248 | $10K | |
| 83690 | <1% | 2,534 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 897 | $10K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 58 | $9K |
| 84702 | <1% | 1,097 | $9K | |
| 88342 | <1% | 360 | $9K | |
| 85651 | <1% | 1,710 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,655 | $8K |
| 73030 | <1% | 249 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,649 | $7K |
| 86803 | <1% | 575 | $7K | |
| 73562 | <1% | 157 | $7K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 140 | $7K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,454 | $7K |
| 73080 | <1% | 119 | $6K | |
| 87077 | <1% | 1,427 | $6K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 75 | $6K |
| 85014 | <1% | 1,998 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,211 | $5K |
| A0425 | Ground mileage, per statute mile | <1% | 3,983 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,337 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 65 | $5K |
| 85018 | <1% | 1,252 | $5K | |
| 82728 | <1% | 927 | $5K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 166 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 42 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 56 | $4K |
| 82607 | <1% | 644 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $4K |
| 82962 | <1% | 3,493 | $4K | |
| 73560 | <1% | 64 | $4K | |
| 81025 | <1% | 480 | $4K | |
| 74018 | <1% | 111 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 39 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 184 | $3K |
| 83605 | <1% | 993 | $3K | |
| 73610 | <1% | 89 | $3K | |
| 73552 | <1% | 107 | $3K | |
| 83615 | <1% | 729 | $3K | |
| 87186 | <1% | 980 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 516 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 21 | $3K |
| 73130 | <1% | 50 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,625 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,520 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 346 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,504 | $3K |
| 83516 | <1% | 160 | $3K | |
| C1769 | Guide wire | <1% | 250 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,281 | $2K |
| 84466 | <1% | 415 | $2K | |
| 83540 | <1% | 671 | $2K | |
| 82784 | <1% | 150 | $2K | |
| 73564 | <1% | 26 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,057 | $2K |
| 84145 | <1% | 148 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 152 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 82 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,494 | $2K |
| 73521 | <1% | 23 | $2K | |
| 87070 | <1% | 310 | $2K | |
| 73502 | <1% | 54 | $1K | |
| 87581 | <1% | 28 | $1K | |
| 87486 | <1% | 28 | $1K | |
| 82533 | <1% | 191 | $1K | |
| 93017 | <1% | 14 | $1K | |
| 82746 | <1% | 117 | $1K | |
| 82570 | <1% | 562 | $956.71 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 162 | $952.90 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 14 | $945.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 723 | $885.15 |
| 80047 | <1% | 277 | $883.26 | |
| 84100 | <1% | 906 | $873.76 | |
| 87205 | <1% | 184 | $850.80 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 83 | $790.45 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 136 | $736.60 |
| 97162 | <1% | 25 | $697.44 | |
| 82140 | <1% | 168 | $646.69 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 14 | $637.95 |
| 97161 | <1% | 14 | $625.93 | |
| 80074 | <1% | 82 | $589.57 | |
| 87040 | <1% | 79 | $556.14 | |
| 96417 | <1% | 17 | $532.66 | |
| 71250 | <1% | 15 | $530.86 | |
| 82043 | <1% | 242 | $512.67 | |
| 36416 | <1% | 137 | $507.60 | |
| 84425 | <1% | 14 | $490.86 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 156 | $484.92 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,102 | $462.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 516 | $461.50 |
| 82378 | <1% | 113 | $447.85 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 65 | $413.13 |
| 74019 | <1% | 13 | $378.23 | |
| 88341 | <1% | 56 | $369.85 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 31 | $357.05 |
| 86038 | <1% | 64 | $354.80 | |
| 85055 | <1% | 22 | $349.93 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 323 | $348.77 |
| 87210 | <1% | 70 | $332.03 | |
| 96367 | <1% | 17 | $315.12 | |
| 76937 | <1% | 12 | $294.23 | |
| 85007 | <1% | 52 | $263.39 | |
| C9399 | Unclassified drugs or biologicals | <1% | 13 | $258.93 |
| 90686 | <1% | 15 | $223.90 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 74 | $193.44 |
| 82550 | <1% | 110 | $191.56 | |
| 82777 | <1% | 26 | $183.57 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 28 | $171.95 |
| 82803 | <1% | 31 | $154.37 | |
| 80320 | <1% | 28 | $135.54 | |
| 82150 | <1% | 27 | $135.12 | |
| 87147 | <1% | 44 | $126.96 | |
| 82040 | <1% | 15 | $123.92 | |
| 81003 | <1% | 29 | $122.19 | |
| 82330 | <1% | 26 | $107.14 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 16 | $106.07 |
| 83970 | <1% | 14 | $99.80 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 28 | $98.90 |
| 80164 | <1% | 17 | $92.07 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $84.02 |
| 84156 | <1% | 12 | $79.53 | |
| 86706 | <1% | 12 | $68.66 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 60 | $60.11 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 38 | $58.07 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $52.72 |
| 36591 | <1% | 80 | $45.46 | |
| 84132 | <1% | 32 | $38.94 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 14 | $23.17 |
| 82375 | <1% | 13 | $23.16 | |
| 82565 | <1% | 15 | $9.08 | |
| 84520 | <1% | 15 | $7.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKENZIE, TERRY (DIRECTOR OF GOVERNMENT REIMBURSEMEN)